Sanofi-Aventis S.A. ADR (SNY)

$42.42 -0.44 (-1.03%)
Market Cap 103.66B
Revenue (ttm) 52.85B
Net Income (ttm) 8.84B
EPS (ttm) N/A
PE Ratio 9.44
Forward PE 8.70
Profit Margin 16.72%
Debt to Equity Ratio 0.25
Volume 3,179,100
Avg Vol 3,217,462
Day's Range N/A - N/A
Shares Out 2.44B
Stochastic %K 9%
Beta 0.35
Analysts Sell
Price Target $55.01

Company Profile

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscienti...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 33 1 53 77 40 00
Address:
46, avenue de la Grande ArmEe, Paris, France
Sha_B_Ral
Sha_B_Ral May. 13 at 10:29 PM
$SNY
0 · Reply
clan
clan May. 13 at 4:27 PM
$NVO $LLY $SNY Inhalable insulin is the next evolutionary step in mealtime insulin for best time in range (TIR). #AFREZZA 🚫💉
0 · Reply
Coopcoop
Coopcoop May. 13 at 3:34 PM
$SNY
1 · Reply
Quantumup
Quantumup May. 13 at 11:32 AM
Wells Fargo⬆️the PT on $CLDX to $54 from $38, reiterated at Overweight, and said: We are getting more constructive on CLDX ahead of barzo's PN readout in mid-2026. $SNY - REGN $GALDY NVS JSPR Wells Fargo added—We believe the Street underappreciates the biological rationale, supportive Ph1b data and the role mast-cell depletion may play in the PN itch-scratch cycle. Barzo's Ph2 PN program appears well de-risked. KIT-driven mast cell depletion may disrupt the itch scratch cycle with added rationale from Nemluvio, which inhibits IL-31, a pruritogenic cytokine produced by mast cells and is approved in PN. Supportive Ph1b biomarker activity aligned with clinical responses, while early efficacy compared favorably vs. dupi/Nemluvio despite limited sample size and single-dose exposure. Durable CSU/ CIndU responses further support translational readthrough to PN.
0 · Reply
BraJack
BraJack May. 12 at 4:14 PM
$SNY big pharma tape steady but needs momentum to clear the slow grind
0 · Reply
ddirk
ddirk May. 12 at 11:15 AM
$SNY anybody know if Sanofi is working on a preclinical study involving the Andes virus like Moderna
0 · Reply
Ultrasound
Ultrasound May. 11 at 10:55 PM
$ALT If this is Garijo's first post as $SNY CEO - I can only image if other Sanofi alumni are saying the same thing about a return to a company that shaped THEIR formative years... Yes, Durso, Pisano, Arbet-Engels, Richardson, Fajolle, I'm speaking to you... make us proud, bring it home!
0 · Reply
outlawinvestor1
outlawinvestor1 May. 11 at 8:58 PM
$CATX $SNY alphamedix tox issues were documented at a radioactivity cap of 5.5 mCi. perspective has now cleared this threshold, treating 20 patients in cohort 3 at 6.0 mCi with zero cases of dysphagia reported as of the march 4, 2026, data cut. this was presented at aacr (in 16 pts). now, they've opened Cohort 4 specifically to test that "front-loaded" dosing strategy! https://perspectivetherapeutics.com/newsroom/press-release?i=165655
0 · Reply
Wallst45
Wallst45 May. 11 at 8:40 AM
$SNY sinking ship what next for this. ??
1 · Reply
BTC321
BTC321 May. 11 at 8:27 AM
$NVAX novavax solves this with french partner sanofi $SNY vaccines stocks soaring! https://x.com/drericding/status/2053739534844604614?s=46&t=X6qO3UejysWvD0UxMTsJrA
0 · Reply
Latest News on SNY
3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally

Wed, 13 May 2026 13:15:00 -0400 - 8 hours ago

3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally

Sanofi's Strategic Acquisition of AgomAb Therapeutics NV Shares

2026-05-13T01:30:23.000Z - 23 hours ago

Sanofi's Strategic Acquisition of AgomAb Therapeutics NV Shares

Shirley Ballas looks back: ‘I was crying about a breakup, so Mum smacked me round the face’

2026-05-10T13:00:27.000Z - 3 days ago

Shirley Ballas looks back: ‘I was crying about a breakup, so Mum smacked me round the face’

Sanofi asks to pull diabetes drug out of FDA voucher program, STAT News reports

Wed, 06 May 2026 14:38:21 -0400 - 7 days ago

Sanofi asks to pull diabetes drug out of FDA voucher program, STAT News reports

Sanofi Supports AlphaDetect to Accelerate Detection of Alpha-1

Wed, 06 May 2026 12:42:00 -0400 - 7 days ago

Sanofi Supports AlphaDetect to Accelerate Detection of Alpha-1

This Small Biotech — Taking On AbbVie, Novartis And Sanofi — Just Catapulted Into A Breakout

2026-05-06T14:04:57.000Z - 7 days ago

This Small Biotech — Taking On AbbVie, Novartis And Sanofi — Just Catapulted Into A Breakout

Novavax Q1 2026 Earnings Call Transcript

2026-05-06T13:54:56.000Z - 7 days ago

Novavax Q1 2026 Earnings Call Transcript

Regeneron, Sanofi present results from Dupixent Phase 4 trial

2026-05-05T13:50:51.000Z - 8 days ago

Regeneron, Sanofi present results from Dupixent Phase 4 trial

REGN

Sanofi invests C$294M to expand AI Center of Excellence in Toronto

2026-05-04T17:05:27.000Z - 9 days ago

Sanofi invests C$294M to expand AI Center of Excellence in Toronto

Sanofi downgraded to Equal Weight from Overweight at Morgan Stanley

2026-05-01T19:35:22.000Z - 12 days ago

Sanofi downgraded to Equal Weight from Overweight at Morgan Stanley

Ignite Solutions: What the U.S. Pharmaceutical Industry Could Learn from How Africa Solves Patient Access

2026-05-01T12:02:00.000Z - 12 days ago

Ignite Solutions: What the U.S. Pharmaceutical Industry Could Learn from How Africa Solves Patient Access

Merck KgaA's New CEO Kai Beckmann Takes Charge As Belén Garijo Becomes Sanofi CEO

2026-05-01T08:32:24.000Z - 12 days ago

Merck KgaA's New CEO Kai Beckmann Takes Charge As Belén Garijo Becomes Sanofi CEO

Press Release: Annual General Meeting of April 29, 2026 - Belén Garijo appointed as Director and Chief Executive Officer of Sanofi

Wed, 29 Apr 2026 12:00:00 -0400 - 14 days ago

Press Release: Annual General Meeting of April 29, 2026 - Belén Garijo appointed as Director and Chief Executive Officer of Sanofi

Giants Costco, Sanofi, and SAP Raise Dividends by Over 10%

2026-04-28T17:25:00.000Z - 15 days ago

Giants Costco, Sanofi, and SAP Raise Dividends by Over 10%

Sanofi Prices EUR 2.3 Bln Notes Offering Across Three Tranches

2026-04-27T06:44:00.000Z - 16 days ago

Sanofi Prices EUR 2.3 Bln Notes Offering Across Three Tranches

3 Healthcare Stocks That Pay You a Dividend While You Wait for a Recovery

Sat, 25 Apr 2026 01:30:00 -0400 - 18 days ago

3 Healthcare Stocks That Pay You a Dividend While You Wait for a Recovery

Sanofi: Sanofi successfully prices 2.3 billion of bond issue

2026-04-24T18:34:00.000Z - 19 days ago

Sanofi: Sanofi successfully prices 2.3 billion of bond issue

Press Release: Sanofi successfully prices 2.3 billion of bond issue

Apr 24, 2026, 2:30 PM EDT - 19 days ago

Press Release: Sanofi successfully prices 2.3 billion of bond issue

SNY

Sanofi (SNY) Gains EMA's Support for Multiple Sclerosis Treatment

2026-04-24T17:56:34.000Z - 19 days ago

Sanofi (SNY) Gains EMA's Support for Multiple Sclerosis Treatment

Weekly Buzz: Sanofi, Regeneron Pharmaceuticals Get FDA Nod; It's A No For AbbVie, Grace Therapeutics; Eli Lilly Acquires Kelonia

2026-04-24T15:48:00.000Z - 19 days ago

Weekly Buzz: Sanofi, Regeneron Pharmaceuticals Get FDA Nod; It's A No For AbbVie, Grace Therapeutics; Eli Lilly Acquires Kelonia

Weekly Buzz: Sanofi, REGN Get FDA Nod; It's A No For ABBV, GRCE; Eli Lilly Acquires Kelonia

2026-04-24T14:54:00.000Z - 19 days ago

Weekly Buzz: Sanofi, REGN Get FDA Nod; It's A No For ABBV, GRCE; Eli Lilly Acquires Kelonia

Sanofi's Cenrifki Gets Positive CHMP Nod For Secondary Progressive Multiple Sclerosis Treatment

2026-04-24T11:06:00.000Z - 19 days ago

Sanofi's Cenrifki Gets Positive CHMP Nod For Secondary Progressive Multiple Sclerosis Treatment

Sanofi: Sanofi's Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses

2026-04-24T10:12:00.000Z - 19 days ago

Sanofi: Sanofi's Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses

Press Release: Sanofi's Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses

2026-04-24T10:09:31.000Z - 19 days ago

Press Release: Sanofi's Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses

Press Release: Sanofi's Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses

Apr 24, 2026, 6:09 AM EDT - 19 days ago

Press Release: Sanofi's Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses

SNY

Sanofi SA (SNY) Q1 2026 Earnings Call Highlights: Strong Sales Growth and Strategic Developments

2026-04-24T07:04:09.000Z - 19 days ago

Sanofi SA (SNY) Q1 2026 Earnings Call Highlights: Strong Sales Growth and Strategic Developments

Q1 2026 Sanofi SA Earnings Call Transcript

2026-04-24T05:04:05.000Z - 19 days ago

Q1 2026 Sanofi SA Earnings Call Transcript

FDA Approval Broadens Dupixent Use While Sanofi Posts Earnings Beat

2026-04-23T15:02:49.000Z - 20 days ago

FDA Approval Broadens Dupixent Use While Sanofi Posts Earnings Beat

Sanofi Leans On Dupixent For First-Quarter Beat A Week Ahead Of New CEO

2026-04-23T12:54:21.000Z - 20 days ago

Sanofi Leans On Dupixent For First-Quarter Beat A Week Ahead Of New CEO

Sanofi Faces Revenue Replacement Challenge After Dupixent Patent Expiry

2026-04-23T11:51:05.000Z - 20 days ago

Sanofi Faces Revenue Replacement Challenge After Dupixent Patent Expiry

Sanofi Earnings Call Transcript: Q1 2026

Apr 23, 2026, 7:00 AM EDT - 20 days ago

Sanofi Earnings Call Transcript: Q1 2026

Sanofi reports Q1 business EPS EUR 1.88, up 5% reported

2026-04-23T10:23:11.000Z - 20 days ago

Sanofi reports Q1 business EPS EUR 1.88, up 5% reported

Sanofi expects FY26 sales to grow by high single-digit percentage at CER

2026-04-23T10:21:59.000Z - 20 days ago

Sanofi expects FY26 sales to grow by high single-digit percentage at CER

Sanofi (SNY) Exceeds Q1 Expectations with Robust Sales and EPS Growth

2026-04-23T08:56:33.000Z - 20 days ago

Sanofi (SNY) Exceeds Q1 Expectations with Robust Sales and EPS Growth

Sanofi (SNY) and Regeneron (REGN) Gain U.S. Approval for Dupixent in Young Children

2026-04-23T06:58:32.000Z - 20 days ago

Sanofi (SNY) and Regeneron (REGN) Gain U.S. Approval for Dupixent in Young Children

Sanofi (SNY) Q1 Earnings Exceed Expectations with Strong Sales Growth

2026-04-23T06:56:54.000Z - 20 days ago

Sanofi (SNY) Q1 Earnings Exceed Expectations with Strong Sales Growth

Sanofi SA Profit Falls In Q1

2026-04-23T06:36:00.000Z - 20 days ago

Sanofi SA Profit Falls In Q1

Sanofi Posts Higher Sales Amid Leadership Transition

Apr 23, 2026, 2:08 AM EDT - 20 days ago

Sanofi Posts Higher Sales Amid Leadership Transition

SNY

Sanofi Q1 Business Net Income Rises; Reiterates 2026 Guidance

2026-04-23T05:59:48.000Z - 20 days ago

Sanofi Q1 Business Net Income Rises; Reiterates 2026 Guidance

Sanofi's first quarter earnings edges past estimates ahead of CEO change

Apr 23, 2026, 1:35 AM EDT - 20 days ago

Sanofi's first quarter earnings edges past estimates ahead of CEO change

SNY

Sanofi: Q1 2026: double-digit sales and business EPS growth

2026-04-23T05:34:00.000Z - 20 days ago

Sanofi: Q1 2026: double-digit sales and business EPS growth

Sanofi: FDA Approves Dupixent For Young Children With Uncontrolled Chronic Pontaneous Urticaria

2026-04-23T04:54:00.000Z - 20 days ago

Sanofi: FDA Approves Dupixent For Young Children With Uncontrolled Chronic Pontaneous Urticaria

Sanofi (SNY) Receives FDA Approval for Dupixent in Young Patients

2026-04-22T22:52:10.000Z - 21 days ago

Sanofi (SNY) Receives FDA Approval for Dupixent in Young Patients

Regeneron, Sanofi: FDA approves Dupixent for treatment of CSU in ages 2-11

2026-04-22T21:35:22.000Z - 21 days ago

Regeneron, Sanofi: FDA approves Dupixent for treatment of CSU in ages 2-11

REGN

Sanofi: Sanofi and Regeneron's Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria

2026-04-22T21:34:00.000Z - 21 days ago

Sanofi: Sanofi and Regeneron's Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria

Press Release: Sanofi and Regeneron's Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria

Apr 22, 2026, 5:30 PM EDT - 21 days ago

Press Release: Sanofi and Regeneron's Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria

REGN SNY

Sanofi Eyes First On-Body Injector Cancer Therapy As FDA Delays Decision

2026-04-22T11:35:51.000Z - 21 days ago

Sanofi Eyes First On-Body Injector Cancer Therapy As FDA Delays Decision

Sanofi's Tzield Wins Expanded FDA Approval For Young Children At Risk Of Type 1 Diabetes

2026-04-22T09:11:37.000Z - 21 days ago

Sanofi's Tzield Wins Expanded FDA Approval For Young Children At Risk Of Type 1 Diabetes

Sanofi Says FDA Extends Review Of Sarclisa SC By Up To Three Months

2026-04-22T07:06:00.000Z - 21 days ago

Sanofi Says FDA Extends Review Of Sarclisa SC By Up To Three Months

Sanofi (SNY) Gains FDA Approval for Tzield to Treat Young Diabetes Patients

2026-04-22T06:57:54.000Z - 21 days ago

Sanofi (SNY) Gains FDA Approval for Tzield to Treat Young Diabetes Patients

Press Release: Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children

Apr 22, 2026, 1:05 AM EDT - 21 days ago

Press Release: Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children

Press Release: Sanofi provides update on the regulatory submission for Sarclisa subcutaneous in the US

Apr 22, 2026, 1:00 AM EDT - 21 days ago

Press Release: Sanofi provides update on the regulatory submission for Sarclisa subcutaneous in the US

Sanofi downgraded to Neutral from Outperform at BNP Paribas

2026-04-20T08:36:09.000Z - 23 days ago

Sanofi downgraded to Neutral from Outperform at BNP Paribas

Sanofi says COVID-19 vaccine showed better tolerability than Moderna’s

2026-04-18T11:25:17.000Z - 25 days ago

Sanofi says COVID-19 vaccine showed better tolerability than Moderna’s

MRNA

Press Release: Sanofi and Regeneron's Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria

Apr 13, 2026, 1:00 AM EDT - 4 weeks ago

Press Release: Sanofi and Regeneron's Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria

REGN

Press Release: Sanofi's lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP

Apr 7, 2026, 1:00 AM EDT - 5 weeks ago

Press Release: Sanofi's lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP

Press Release: Sanofi's Rezurock approved in the EU to treat chronic graft-vs-host disease

Mar 31, 2026, 1:00 AM EDT - 6 weeks ago

Press Release: Sanofi's Rezurock approved in the EU to treat chronic graft-vs-host disease

Press Release: AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session

Mar 28, 2026, 11:00 AM EDT - 6 weeks ago

Press Release: AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session

EU regulator backs Sanofi's injectable version of blood cancer drug

Mar 27, 2026, 9:36 AM EDT - 6 weeks ago

EU regulator backs Sanofi's injectable version of blood cancer drug

Press release: Availability of the Q1 2026 aide-mémoire

Mar 24, 2026, 2:30 AM EDT - 7 weeks ago

Press release: Availability of the Q1 2026 aide-mémoire

Press Release: Sanofi and Regeneron's Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid

Mar 24, 2026, 2:00 AM EDT - 7 weeks ago

Press Release: Sanofi and Regeneron's Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid

REGN

Kali Therapeutics signs deal with Sanofi to develop autoimmune treatment

Mar 23, 2026, 7:57 AM EDT - 7 weeks ago

Kali Therapeutics signs deal with Sanofi to develop autoimmune treatment

Sanofi launches innovation and operation centre in China

Mar 20, 2026, 10:58 AM EDT - 7 weeks ago

Sanofi launches innovation and operation centre in China

TrumpRx lists many medicines at prices higher than paid in UK

Mar 18, 2026, 2:23 PM EDT - 2 months ago

TrumpRx lists many medicines at prices higher than paid in UK

ABBV AMGN AZN BMY GILD GSK JNJ

Mirecule Expands Strategic FSHD Collaboration with Sanofi

Mar 18, 2026, 7:00 AM EDT - 2 months ago

Mirecule Expands Strategic FSHD Collaboration with Sanofi

Press Release: Sanofi's venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease

Mar 18, 2026, 2:00 AM EDT - 2 months ago

Press Release: Sanofi's venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease

Big drugmakers must face US overcharge claims on medications for low-income patients

Mar 17, 2026, 2:32 PM EDT - 2 months ago

Big drugmakers must face US overcharge claims on medications for low-income patients

ABBV AZN NVS

The Big 3: PR, ELF, SNY

Mar 17, 2026, 1:27 PM EDT - 2 months ago

The Big 3: PR, ELF, SNY

ELF PR

Sanofi: Information concerning the total number of voting rights and shares - February 2026

Mar 12, 2026, 1:30 PM EDT - 2 months ago

Sanofi: Information concerning the total number of voting rights and shares - February 2026

Brazil drugmaker EMS eyes overseas deals after buying Sanofi unit

Mar 10, 2026, 4:16 PM EDT - 2 months ago

Brazil drugmaker EMS eyes overseas deals after buying Sanofi unit

Press Release:  Sanofi's Board of Directors proposes the appointment of Christel Heydemann as an independent director

Mar 5, 2026, 3:16 AM EST - 2 months ago

Press Release:  Sanofi's Board of Directors proposes the appointment of Christel Heydemann as an independent director

Press Release: Filing of an amendment to the French “Document d'Enregistrement Universel” containing the Annual Financial Report

Mar 4, 2026, 12:30 PM EST - 2 months ago

Press Release: Filing of an amendment to the French “Document d'Enregistrement Universel” containing the Annual Financial Report

Sino Biopharm unit licenses blood cancer drug to Sanofi for up to $1.53 bln

Mar 3, 2026, 6:13 PM EST - 2 months ago

Sino Biopharm unit licenses blood cancer drug to Sanofi for up to $1.53 bln

Press Release: Sanofi's rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease

Mar 2, 2026, 1:00 AM EST - 2 months ago

Press Release: Sanofi's rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease

Press Release: Sanofi and Regeneron's Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment

Feb 27, 2026, 7:03 AM EST - 2 months ago

Press Release: Sanofi and Regeneron's Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment

REGN

Press Release: Acoziborole Winthrop, developed by DNDi and Sanofi, receives CHMP positive opinion as three-tablet, single-dose treatment for most common form of sleeping sickness

Feb 27, 2026, 5:55 AM EST - 2 months ago

Press Release: Acoziborole Winthrop, developed by DNDi and Sanofi, receives CHMP positive opinion as three-tablet, single-dose treatment for most common form of sleeping sickness

Press Release: Sanofi and Regeneron's Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis

Feb 24, 2026, 9:30 AM EST - 2 months ago

Press Release: Sanofi and Regeneron's Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis

REGN

Texas sues Sanofi for allegedly 'bribing' providers to boost drug prescriptions

Feb 19, 2026, 6:06 PM EST - 2 months ago

Texas sues Sanofi for allegedly 'bribing' providers to boost drug prescriptions

Press release: Filing of the 2025 U.S. Form 20-F and French “Document d'Enregistrement Universel” containing the Annual Financial Report

Feb 17, 2026, 1:00 PM EST - 3 months ago

Press release: Filing of the 2025 U.S. Form 20-F and French “Document d'Enregistrement Universel” containing the Annual Financial Report

Sanofi announces leadership evolution in Specialty Care Business Unit

Feb 17, 2026, 8:30 AM EST - 3 months ago

Sanofi announces leadership evolution in Specialty Care Business Unit

Press Release: Sanofi and Teva's duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn's disease

Feb 17, 2026, 6:00 AM EST - 3 months ago

Press Release: Sanofi and Teva's duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn's disease

Drugmaker Sanofi to expand India GCC, increase workforce to over 4,500 employees

Feb 16, 2026, 7:07 AM EST - 3 months ago

Drugmaker Sanofi to expand India GCC, increase workforce to over 4,500 employees

Press Release: Beyfortus study published in The Lancet Infectious Diseases shows benefit for infants beyond first RSV season

Feb 16, 2026, 1:00 AM EST - 3 months ago

Press Release: Beyfortus study published in The Lancet Infectious Diseases shows benefit for infants beyond first RSV season

Sanofi's new CEO needs to fix drug pipeline and navigate Trump

Feb 13, 2026, 1:03 AM EST - 3 months ago

Sanofi's new CEO needs to fix drug pipeline and navigate Trump

Who is Sanofi's new CEO Belén Garijo?

Feb 12, 2026, 3:58 AM EST - 3 months ago

Who is Sanofi's new CEO Belén Garijo?

Sanofi Names Merck KGaA's Garijo to Replace Hudson as CEO

Feb 12, 2026, 2:08 AM EST - 3 months ago

Sanofi Names Merck KGaA's Garijo to Replace Hudson as CEO

Sanofi appoints Belén Garijo as new CEO after deciding not to renew current CEO Hudson's mandate

Feb 12, 2026, 1:47 AM EST - 3 months ago

Sanofi appoints Belén Garijo as new CEO after deciding not to renew current CEO Hudson's mandate

Press Release: Belén Garijo to become Chief Executive Officer of Sanofi

Feb 12, 2026, 1:30 AM EST - 3 months ago

Press Release: Belén Garijo to become Chief Executive Officer of Sanofi

Sanofi: Information concerning the total number of voting rights and shares – January 2026

Feb 11, 2026, 12:30 PM EST - 3 months ago

Sanofi: Information concerning the total number of voting rights and shares – January 2026

Press Release: Sanofi completes the acquisition of Dynavax

Feb 10, 2026, 9:00 AM EST - 3 months ago

Press Release: Sanofi completes the acquisition of Dynavax

Press Release: Sanofi's rilzabrutinib designated breakthrough therapy in the US and orphan drug in Japan for the treatment of warm autoimmune hemolytic anemia

Feb 9, 2026, 1:00 AM EST - 3 months ago

Press Release: Sanofi's rilzabrutinib designated breakthrough therapy in the US and orphan drug in Japan for the treatment of warm autoimmune hemolytic anemia

UK industry body says Sanofi in breach over RSV therapy claims against Pfizer

Feb 2, 2026, 8:42 AM EST - 3 months ago

UK industry body says Sanofi in breach over RSV therapy claims against Pfizer

PFE

Sanofi's genetic disorder drug shows mixed results in late-stage trials

Feb 2, 2026, 1:02 AM EST - 3 months ago

Sanofi's genetic disorder drug shows mixed results in late-stage trials

Press Release: Sanofi's Rezurock recommended for EU approval by the CHMP to treat chronic graft-vs-host disease

Jan 30, 2026, 7:00 AM EST - 3 months ago

Press Release: Sanofi's Rezurock recommended for EU approval by the CHMP to treat chronic graft-vs-host disease

Sha_B_Ral
Sha_B_Ral May. 13 at 10:29 PM
$SNY
0 · Reply
clan
clan May. 13 at 4:27 PM
$NVO $LLY $SNY Inhalable insulin is the next evolutionary step in mealtime insulin for best time in range (TIR). #AFREZZA 🚫💉
0 · Reply
Coopcoop
Coopcoop May. 13 at 3:34 PM
$SNY
1 · Reply
Quantumup
Quantumup May. 13 at 11:32 AM
Wells Fargo⬆️the PT on $CLDX to $54 from $38, reiterated at Overweight, and said: We are getting more constructive on CLDX ahead of barzo's PN readout in mid-2026. $SNY - REGN $GALDY NVS JSPR Wells Fargo added—We believe the Street underappreciates the biological rationale, supportive Ph1b data and the role mast-cell depletion may play in the PN itch-scratch cycle. Barzo's Ph2 PN program appears well de-risked. KIT-driven mast cell depletion may disrupt the itch scratch cycle with added rationale from Nemluvio, which inhibits IL-31, a pruritogenic cytokine produced by mast cells and is approved in PN. Supportive Ph1b biomarker activity aligned with clinical responses, while early efficacy compared favorably vs. dupi/Nemluvio despite limited sample size and single-dose exposure. Durable CSU/ CIndU responses further support translational readthrough to PN.
0 · Reply
BraJack
BraJack May. 12 at 4:14 PM
$SNY big pharma tape steady but needs momentum to clear the slow grind
0 · Reply
ddirk
ddirk May. 12 at 11:15 AM
$SNY anybody know if Sanofi is working on a preclinical study involving the Andes virus like Moderna
0 · Reply
Ultrasound
Ultrasound May. 11 at 10:55 PM
$ALT If this is Garijo's first post as $SNY CEO - I can only image if other Sanofi alumni are saying the same thing about a return to a company that shaped THEIR formative years... Yes, Durso, Pisano, Arbet-Engels, Richardson, Fajolle, I'm speaking to you... make us proud, bring it home!
0 · Reply
outlawinvestor1
outlawinvestor1 May. 11 at 8:58 PM
$CATX $SNY alphamedix tox issues were documented at a radioactivity cap of 5.5 mCi. perspective has now cleared this threshold, treating 20 patients in cohort 3 at 6.0 mCi with zero cases of dysphagia reported as of the march 4, 2026, data cut. this was presented at aacr (in 16 pts). now, they've opened Cohort 4 specifically to test that "front-loaded" dosing strategy! https://perspectivetherapeutics.com/newsroom/press-release?i=165655
0 · Reply
Wallst45
Wallst45 May. 11 at 8:40 AM
$SNY sinking ship what next for this. ??
1 · Reply
BTC321
BTC321 May. 11 at 8:27 AM
$NVAX novavax solves this with french partner sanofi $SNY vaccines stocks soaring! https://x.com/drericding/status/2053739534844604614?s=46&t=X6qO3UejysWvD0UxMTsJrA
0 · Reply
jheerdink
jheerdink May. 7 at 4:43 PM
$EPRX https://vistapglobal.com/from-weekly-jabs-to-yearly-scopes-why-eupraxias-ep-104gi-might-have-sanofi-checking-its-calendar-eprx-sny-xbi/ $SNY
0 · Reply
StocktwitsNews
StocktwitsNews May. 7 at 6:47 AM
NVAX Stock Eyes Breakout Week: Novavax Claims Patients Were ‘Twice As Likely’ To Pick Its COVID Shot Over Moderna Again $NVAX $PFE $MRNA $SNY https://stocktwits.com/news/equity/markets/nvax-stock-breakout-week-covid-shot-over-moderna-again/cZXb2xNRef1
0 · Reply
Saihati
Saihati May. 6 at 8:49 PM
$SNY What does history tell us when we see a weekly red hollow candlestick in the bottom of a downtrend? 🤔
2 · Reply
BTC321
BTC321 May. 6 at 5:09 PM
$NVAX $SNY exactly!!
2 · Reply
Rickt310
Rickt310 May. 6 at 4:57 PM
$NVAX $SNY do you think Shaw is going to change his position now on the proxy vote
0 · Reply
BTC321
BTC321 May. 6 at 3:13 PM
$NVAX with the new results of the combi vax sanofi $SNY and novavax matrix m we could beeak $10 today!!! this is freakin MaSSIVE!!!!
1 · Reply
Dilly_Due
Dilly_Due May. 5 at 9:56 PM
$VXRT Oral, licensed, $50 mil. milestones, 6-10% royalty, $6.3 Bil. market cap,........ooooooooh! Sounds familiar, maybe except the royalty is a bit low. Why did $SNY pay "low to mid teens"? Because it's worth it! Just my humble opinion. Do your own DD. https://finance.yahoo.com/sectors/healthcare/articles/protagonist-reports-first-quarter-2026-200500536.html
0 · Reply
dcajic2
dcajic2 May. 4 at 5:17 PM
$SNY just been a huge disappointment owning this company. Sold 1/2 last week when I basically broke even. Should have sold everything.
1 · Reply
JuggernautRaider
JuggernautRaider May. 3 at 1:56 PM
$IMRX i wonder when $SNY will buy the rest of this pancreatic cancer pipeline with similar OS rates to $RVMD yet at a fraction of the market cap? 🤔
1 · Reply
MQuick
MQuick May. 1 at 5:09 PM
$GANX its time $SNY
0 · Reply
Dilly_Due
Dilly_Due May. 1 at 3:29 PM
$VXRT Random shoutout to the $SNY executive who may have engineered the VAAST Covid license acquisition through Dynavax followed by the fast $DVAX closing. There are people out there that think this was a blinded lottery ticket. I don't believe anything like this happens by accident. Fast forward a few months and Vaxart has a new board member. He has a background that reflects humanitarianism with his work for Facioscapulohumeral muscular dystrophy (FSHD), 10 years in oncology therapeutic development and 5 years at Lilly in a very interesting VP role! Could Lilly also be interested? They have a HUGE chunk of revenue tied to Zepbound that they need to diversify. VAAST could help do that! Could Vaxart be positioning to go it alone? (again, check that Lilly work below). Better hurry up $SNY . Just my humble opinions. Do your own DD. VERY....
2 · Reply
Quantumup
Quantumup May. 1 at 2:51 PM
BRiley🏁 $UNCY Buy; $22—the investment thesis focuses on OLC, Unicycive's next-generation nanoparticle-formulated lanthanum-based phosphate binder w/ a June 29 FDA action date, positioned to enter a $1.5B U.S. hyperphosphatemia market. $ARDX $SNY TAK AKBA MAZE BRiley added in its initiation report—Oxylanthanum carbonate is the only TDAPA-eligible phosphate-lowering therapy at the precise moment that class-level TDAPA for the six existing bundled binders expires.
0 · Reply